US5494656A - Second sphere complexes as relaxation agents for image enhancement in magnetic resonance imaging - Google Patents

Second sphere complexes as relaxation agents for image enhancement in magnetic resonance imaging Download PDF

Info

Publication number
US5494656A
US5494656A US08/406,356 US40635695A US5494656A US 5494656 A US5494656 A US 5494656A US 40635695 A US40635695 A US 40635695A US 5494656 A US5494656 A US 5494656A
Authority
US
United States
Prior art keywords
iii
metal ion
paramagnetic metal
ligand
sphere
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
US08/406,356
Inventor
Julian A. Davies
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Toledo
Original Assignee
University of Toledo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Toledo filed Critical University of Toledo
Priority to US08/406,356 priority Critical patent/US5494656A/en
Application granted granted Critical
Publication of US5494656A publication Critical patent/US5494656A/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
    • G01R33/00—Arrangements or instruments for measuring magnetic variables
    • G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
    • G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
    • G01R33/48—NMR imaging systems
    • G01R33/54—Signal processing systems, e.g. using pulse sequences ; Generation or control of pulse sequences; Operator console
    • G01R33/56—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution
    • G01R33/5601—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution involving use of a contrast agent for contrast manipulation, e.g. a paramagnetic, super-paramagnetic, ferromagnetic or hyperpolarised contrast agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/41—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing singly-bound oxygen atoms bound to the carbon skeleton
    • C07C309/42—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing singly-bound oxygen atoms bound to the carbon skeleton having the sulfo groups bound to carbon atoms of non-condensed six-membered aromatic rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/24—Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry

Definitions

  • This invention relates generally to second sphere complexes useful as relaxation agents for image enhancement in magnetic resonance imaging. More particularly, the invention is directed to second sphere complexes comprising paramagnetic metal ions having catecholate ligands coordinated thereto and having water molecules hydrogen bonded to said ligands, and to a method for performing magnetic resonance imaging of a patient using said second sphere complexes.
  • Magnetic resonance imaging is a nuclear magnetic resonance (NMR) technique which may be used clinically to differentiate between normal and abnormal tissues.
  • NMR nuclear magnetic resonance
  • the 1 H NMR imaging method is based upon differences in water proton concentrations and relaxation rates within different tissue types.
  • contrast agents such as paramagnetic metal chelates to enhance the diagnostic utility of MRI has only recently became practical.
  • U.S. Pat. No. 4,880,008 to Lauffer discloses in vivo enhancement of NMR relaxivity utilizing chelated paramagnetic ions such as iron(III) and gadolinium(III).
  • the chelating substances include bis, tris, and tetracatechol compounds.
  • U.S. Pat. No. 5,010,191 to Engelstad et al. discloses imaging agents for in vivo magnetic resonance and scintigraphic imaging, including chelated transition metal and lanthanide metal complexes.
  • the patent discloses a comparison screening protocol including the iron(III) chelate of TIRON®.
  • the patent does not disclose the second sphere iron(III) complex of the salt of disodium-1,2-dihydroxybenzene-3,5-disulfonate having water molecules hydrogen bonded to the ligand groups.
  • second sphere complexes useful as relaxation agents for image enhancement in magnetic resonance imaging have surprisingly been discovered.
  • These complexes include paramagnetic metal ions chelated with catecholate ligands, wherein water molecules are hydrogen bonded to the ligands.
  • Also contemplated by the present invention is a method for magnetic resonance image enhancement utilizing said second sphere complexes.
  • Paramagnetic species such as certain complexes of memal ions, can alter the longitudinal and/or transverse relaxation rates of adjacent nuclei by dipolar interactions.
  • the metal ions with the most suitable magnetic moments and relaxation efficiencies for this purpose are gadolinium(III) and iron(III).
  • gadolinium(III) and iron(III) In order for the metal ion to enhance the relaxation rate of water protons in tissue, it is important that the water molecules approach close to the paramagnetic center. It is believed that three basic types of interactions between the metal ion and water molecules may occur. In an inner sphere interaction, water molecules bind to and exchange with the metal ion, for a very effective contact.
  • the metal ion coordination sites are occupied by a set of ligands, and so water molecules are affected only through translational diffusion past the paramagnetic center.
  • the metal ion is surrounded by a set of ligands which prevent direct coordination of water molecules to the metal ion.
  • the ligands of a second sphere complex also provide bonding sites for the hydrogen bonding of water molecules thereto.
  • Metal ions which interact with water molecules by an inner sphere mechanism are very effective for enhancing relaxation rates, but such ions generally exhibit very high toxicities.
  • the origin of this toxicity lies in the availability of coordination sites at the metal ion center which leads to binding by not only water molecules but also by activated oxygen, nitrogen, or sulfur groups of a lumber of biomolecules.
  • the coordination sites at the metal center can essentially be removed by using a suitable set of ligands. However, although this reduces toxicity, it typically leaves only the less-effective outer sphere interactions with water molecules to provide relaxation rate enhancement. To balance these effects, complexes designed to operate by second sphere interactions have been developed herein for use in magnetic resonance imaging.
  • the ligands useful for second sphere relaxation enhancement must meet specific requirements. They must bind strongly to paramagnetic metal ions, since ligand dissociation would result in metal ion toxicity and ligand-derived organic toxicity. Useful ligands must form complexes which are excreted efficiently to prevent long term toxicity by, for example, the accumulation of lipophilic complexes in membranes or retention by cells in the reticular endothelial system. Moreover, the useful ligands must provide sites for the hydrogen bonding of water molecules.
  • the mechanism of efficient excretion of the complexes from the body which preferably should occur within a few hours following administration, is less-well understood. Only certain broad principles are available to assist in the complex design. Thus, the presence of highly charged and/or hydrogen bonded groups and the absence of lipophilic side chains minimizes interactions with membranes, plasma proteins, etc., and so allows for effective renal excretion. Certain anionic complexes are excreted by the hepatobiliary pathway in competition with excretion via the kidneys. Although poorly understood, excretion via the liver may involve transport of anionic complexes by the same agents that transport fatty acids, bile acids, and heme degradation products. Thus, for efficient excretion to avoid long term toxicity, the factors promoting both renal and hepatobiliary pathways must be maximized.
  • the second sphere complexes of the present invention comply with the requirements set forth above.
  • the inventive complexes are prepared utilizing paramagnetic metal ions, which are detectable in their chelated form by magnetic resonance imaging, such as, for example, iron(III), gadolinium(III), manganese (II and III), chromium(III), copper(II), dysprosium(III), terbium(III), holmium (III), erbium (III), and europium (III) .
  • Preferred paramagnetic metal ions comprise iron(III) and gadolinium(III).
  • Suitable ligands for preparing the second sphere complexes according to the present invention include catecholate systems prepared from, for example, derivatives of 1,2-benzenediol (catechol) such as the salt disodium-1,2-dihydroxybenzene-3,5-disulfonate.
  • a preferred ligand comprises the salt disodium-1,2-dihydroxybenzene-3,5-disulfonate.
  • the pendant sulfonate groups act as additional hydrogen bonding sites for water molecules.
  • the second sphere complexes of the present invention may be administered in any convenient manner to the subject.
  • the complexes may be dissolved in a saline solution and injected intravenously or subcutaneously.
  • the dosages will be limited to only those amounts necessary and sufficient to allow detection by magnetic resonance imaging.
  • Such dosages typically range from about 0.05 mmol kg -1 to about 0.03 mmol kg -1 .
  • the dosages range from about 0.1 mmol kg -1 to about 0.2 mmol kg -1 .
  • the second sphere complexes of the present invention enhance magnetic resonance imaging conducted utilizing conventional nuclear magnetic resonance devices.
  • the complexes shorten the imaging time required to produce and maintain images of the target tissues.
  • This complex has second-sphere water molecules coordinated to ligand sites.
  • DPTA diethylenetriaminepentaacetic acid
  • This complex has second-sphere water molecules coordinated to ligand sites.
  • the solutions for Examples 1 and 2 are prepared in such a manner that a dose of 0.5 mL would deliver the appropriate amount of agent for the body weight of a subject, e.g. 0.1 mmol per kg of body weight.
  • the pH of the solutions are adjusted to near-physiologic value (ca. 7.4) and the solutions are passed through a filtration device to remove particulate matter.
  • a typical solution is prepared as follows: iron(III) nitrate (one equivalent) and disodium-1,2-dihydroxybenzene-3,5-disulfonate (three equivalents) are added together in distilled, deionized water.
  • the pH is adjusted with hydrochloric acid and/or ammonium hydroxide to ca.
  • the concentration of iron(III) adjusted to the desired level (such that, for example, 0.5 mL delivers 0.1 mmol per kg of body weight for the subject under investigation) with distilled, deionized water.
  • the iron(III) tris(TIRON®) complex self-assembles with second sphere water molecules.
  • Example and Comparison solutions are imaged in an MRI unit under conditions designed to explore differences caused by changes in longitudinal relaxation.
  • Results of region-of-interest (ROI) measurements can be plotted against concentration to illustrate the effect of the different complexes on image brightness.
  • Example 1 and Comparison 1 give about the same intensity maxima, despite the fact that the Gd(III) complex has one inner sphere water molecule and the Fe(III) complex has no inner sphere water molecules. Thus, the second sphere effect is evident for the Fe(III) complex.
  • aqueous solutions of the second-sphere complex were prepared at a pH of ca. 7.4 and filtered.
  • the aqueous solutions of the second-sphere complex were administered to anaesthetized male fisher rats in amounts of 0.05 mmol kg -1 , 0.10 mmol kg -1 and 0 15 mmol kg -1 .
  • the animals were imaged in the head coil of a conventional MRI unit with a pulse sequence designed to emphasize differences in T 1 (T 1 weighted sequence).
  • the resulting images were analyzed numerically by region-of-interest (ROI) measurements on various organs. The intensity of the kidney image, as indicated by the ROI measurements, increases from ca.
  • ROI region-of-interest
  • ca. 400 0.05 mmol kg -1
  • ca 500 (0.10 mmol kg.sup. -1
  • ca 600 (0.15 mmol kg -1 ) as the dose is increased.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Signal Processing (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • General Physics & Mathematics (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

A second sphere contrast enhancing agent for magnetic resonance imaging comprises a paramagnetic metal ion having catecholate ligands coordinated thereto and having water molecules hydrogen bonded to the catecholate ligands.

Description

This application is a continuation of application Ser. No. 08/121,227, filed Sep. 14, 1993 abandoned.
FIELD OF THE INVENTION
This invention relates generally to second sphere complexes useful as relaxation agents for image enhancement in magnetic resonance imaging. More particularly, the invention is directed to second sphere complexes comprising paramagnetic metal ions having catecholate ligands coordinated thereto and having water molecules hydrogen bonded to said ligands, and to a method for performing magnetic resonance imaging of a patient using said second sphere complexes.
BACKGROUND OF THE INVENTION
Magnetic resonance imaging (MRI) is a nuclear magnetic resonance (NMR) technique which may be used clinically to differentiate between normal and abnormal tissues. The 1 H NMR imaging method is based upon differences in water proton concentrations and relaxation rates within different tissue types. The use of contrast agents such as paramagnetic metal chelates to enhance the diagnostic utility of MRI has only recently became practical.
U.S. Pat. No. 4,880,008 to Lauffer discloses in vivo enhancement of NMR relaxivity utilizing chelated paramagnetic ions such as iron(III) and gadolinium(III). The chelating substances include bis, tris, and tetracatechol compounds.
U.S. Pat. No. 5,010,191 to Engelstad et al. discloses imaging agents for in vivo magnetic resonance and scintigraphic imaging, including chelated transition metal and lanthanide metal complexes. The patent discloses a comparison screening protocol including the iron(III) chelate of TIRON®. However, the patent does not disclose the second sphere iron(III) complex of the salt of disodium-1,2-dihydroxybenzene-3,5-disulfonate having water molecules hydrogen bonded to the ligand groups.
SUMMARY OF THE INVENTION
Accordant with the present invention, second sphere complexes useful as relaxation agents for image enhancement in magnetic resonance imaging have surprisingly been discovered. These complexes include paramagnetic metal ions chelated with catecholate ligands, wherein water molecules are hydrogen bonded to the ligands. Also contemplated by the present invention is a method for magnetic resonance image enhancement utilizing said second sphere complexes.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT
The development of pharmaceutical agents which enhance image contrast between tissue types presents unique challenges since such agents are not themselves imaged but rather function through affecting water molecule proton relaxation rates. This important distinction between image contrast agents and other types of clinically useful diagnostic pharmaceuticals, such as for example X-ray contrast agents or radiopharmaceuticals, leads to major differences in the in vivo distribution requirements of each type of agent. Thus, for a magnetic resonance imaging contrast agent to be effective, it is not required that the agent localize in the target tissue, but rather that the water proton relaxation rate in the target tissue be affected differently from the relaxation rate of the water protons in the surrounding tissue. Such differentiation without preferential localization of the contrast agent is possible because of the mode of action of these image enhancement agents.
Paramagnetic species, such as certain complexes of memal ions, can alter the longitudinal and/or transverse relaxation rates of adjacent nuclei by dipolar interactions. The metal ions with the most suitable magnetic moments and relaxation efficiencies for this purpose are gadolinium(III) and iron(III). In order for the metal ion to enhance the relaxation rate of water protons in tissue, it is important that the water molecules approach close to the paramagnetic center. It is believed that three basic types of interactions between the metal ion and water molecules may occur. In an inner sphere interaction, water molecules bind to and exchange with the metal ion, for a very effective contact. In an outer sphere interaction, all of the metal ion coordination sites are occupied by a set of ligands, and so water molecules are affected only through translational diffusion past the paramagnetic center. In an intermediate case, i.e., second sphere interaction, the metal ion is surrounded by a set of ligands which prevent direct coordination of water molecules to the metal ion. However, the ligands of a second sphere complex also provide bonding sites for the hydrogen bonding of water molecules thereto.
Metal ions which interact with water molecules by an inner sphere mechanism are very effective for enhancing relaxation rates, but such ions generally exhibit very high toxicities. The origin of this toxicity lies in the availability of coordination sites at the metal ion center which leads to binding by not only water molecules but also by activated oxygen, nitrogen, or sulfur groups of a lumber of biomolecules. The coordination sites at the metal center can essentially be removed by using a suitable set of ligands. However, although this reduces toxicity, it typically leaves only the less-effective outer sphere interactions with water molecules to provide relaxation rate enhancement. To balance these effects, complexes designed to operate by second sphere interactions have been developed herein for use in magnetic resonance imaging.
The ligands useful for second sphere relaxation enhancement must meet specific requirements. They must bind strongly to paramagnetic metal ions, since ligand dissociation would result in metal ion toxicity and ligand-derived organic toxicity. Useful ligands must form complexes which are excreted efficiently to prevent long term toxicity by, for example, the accumulation of lipophilic complexes in membranes or retention by cells in the reticular endothelial system. Moreover, the useful ligands must provide sites for the hydrogen bonding of water molecules.
The requirement for strong paramagnetic metal ion-to-ligand binding is well understood. Thus, the diethylenetriaminepentaacetic acid complex of gadolinium(III), with an association constant K(ML) of 22.5, is excreted intact and so exhibits a low toxicity. However, the analogous ethylenediaminetetraacetic acid complex of gadolinium(III) with an association constant K(ML) of 17.35 exhibits a toxicity comparable to the free, aqueous gadolinium(III) ion, thereby suggesting in vivo dissociation.
The mechanism of efficient excretion of the complexes from the body, which preferably should occur within a few hours following administration, is less-well understood. Only certain broad principles are available to assist in the complex design. Thus, the presence of highly charged and/or hydrogen bonded groups and the absence of lipophilic side chains minimizes interactions with membranes, plasma proteins, etc., and so allows for effective renal excretion. Certain anionic complexes are excreted by the hepatobiliary pathway in competition with excretion via the kidneys. Although poorly understood, excretion via the liver may involve transport of anionic complexes by the same agents that transport fatty acids, bile acids, and heme degradation products. Thus, for efficient excretion to avoid long term toxicity, the factors promoting both renal and hepatobiliary pathways must be maximized.
The presence of hydrogen bonded water molecules is critical to the operability and utility of second sphere relaxation complexes, according to the present invention. Complexes which fall into this group rely on the hydrogen bonding of water molecules to the heteroatoms which form the paramagnetic metal ion-to-ligand linkages.
The second sphere complexes of the present invention comply with the requirements set forth above. The inventive complexes are prepared utilizing paramagnetic metal ions, which are detectable in their chelated form by magnetic resonance imaging, such as, for example, iron(III), gadolinium(III), manganese (II and III), chromium(III), copper(II), dysprosium(III), terbium(III), holmium (III), erbium (III), and europium (III) . Preferred paramagnetic metal ions comprise iron(III) and gadolinium(III).
Suitable ligands for preparing the second sphere complexes according to the present invention include catecholate systems prepared from, for example, derivatives of 1,2-benzenediol (catechol) such as the salt disodium-1,2-dihydroxybenzene-3,5-disulfonate. A preferred ligand comprises the salt disodium-1,2-dihydroxybenzene-3,5-disulfonate. The pendant sulfonate groups act as additional hydrogen bonding sites for water molecules.
The second sphere complexes of the present invention may be administered in any convenient manner to the subject. For example, the complexes may be dissolved in a saline solution and injected intravenously or subcutaneously. Generally, the dosages will be limited to only those amounts necessary and sufficient to allow detection by magnetic resonance imaging. Such dosages typically range from about 0.05 mmol kg-1 to about 0.03 mmol kg-1. Preferably, the dosages range from about 0.1 mmol kg-1 to about 0.2 mmol kg-1.
The second sphere complexes of the present invention enhance magnetic resonance imaging conducted utilizing conventional nuclear magnetic resonance devices. The complexes shorten the imaging time required to produce and maintain images of the target tissues.
EXAMPLES 1 and 2
Solutions are prepared containing the following substances for in vitro analysis by NMR:
Example 1
Varying concentrations of the tris(TIRON®)iron(III) complex under conditions of pH where the tris(ligand) complex, with no inner sphere water molecules, is essentially the only iron-containing species in solution. This complex has second-sphere water molecules coordinated to ligand sites.
Comparison 1
Varying concentrations of the Gd(III) complex of the ligand diethylenetriaminepentaacetic acid (DPTA). This is a complex marketed in solution under the trade name MAGNEVIST®, and is known through other studies to have one inner sphere water molecule.
Example 2
Varying concentrations of the tris(catecholate)iron(III) complex under conditions of pH where the tris(ligand) complex, with no inner sphere water molecules, is essentially the only iron-containing species in solution. This complex has second-sphere water molecules coordinated to ligand sites.
Comparison 2
Varying concentrations of the tris(ligand) iron(III) complex of 2,3-dihydroxynaphthalene, a derivative of catechol with hydrophobic groups attached to prevent second sphere coordination of water molecules, under conditions of pH where the tris(ligand) complex is essentially the only iron-containing species in solution. This complex has no second-sphere water molecules coordinated to ligand sites.
The solutions for Examples 1 and 2 are prepared in such a manner that a dose of 0.5 mL would deliver the appropriate amount of agent for the body weight of a subject, e.g. 0.1 mmol per kg of body weight. The pH of the solutions are adjusted to near-physiologic value (ca. 7.4) and the solutions are passed through a filtration device to remove particulate matter. A typical solution is prepared as follows: iron(III) nitrate (one equivalent) and disodium-1,2-dihydroxybenzene-3,5-disulfonate (three equivalents) are added together in distilled, deionized water. The pH is adjusted with hydrochloric acid and/or ammonium hydroxide to ca. 7.4 and the concentration of iron(III) adjusted to the desired level (such that, for example, 0.5 mL delivers 0.1 mmol per kg of body weight for the subject under investigation) with distilled, deionized water. Under these conditions, the iron(III) tris(TIRON®) complex self-assembles with second sphere water molecules.
The Example and Comparison solutions are imaged in an MRI unit under conditions designed to explore differences caused by changes in longitudinal relaxation. Results of region-of-interest (ROI) measurements can be plotted against concentration to illustrate the effect of the different complexes on image brightness.
It is observed that Example 1 and Comparison 1 give about the same intensity maxima, despite the fact that the Gd(III) complex has one inner sphere water molecule and the Fe(III) complex has no inner sphere water molecules. Thus, the second sphere effect is evident for the Fe(III) complex.
Furthermore, it is observed that the maximum intensity for Comparison 2 is low in comparison to Example 2. The hydrophobic groups of the 2,3-dihydroxynaphthalene exclude second sphere water molecules in the solutions of Comparison 2, while the catechol complex Example 2 experiences second sphere coordination.
These results show that: (i) systems with inner sphere water molecules such as Gd(III)-DTPA, are effective; (ii) systems with no inner sphere waters and no second sphere waters, such as the Fe(III) tris(ligand) complex of 2,3-dihydroxynaphthalene, are not effective; and (iii) systems with no inner sphere waters but with second sphere waters, such as the Fe(III) tris(ligand) complexes of catechol and TIRON®, are effective.
EXAMPLE 3
To illustrate the utility of Fe(III) tironate as an MRI contrast agent, aqueous solutions of the second-sphere complex were prepared at a pH of ca. 7.4 and filtered. The aqueous solutions of the second-sphere complex were administered to anaesthetized male fisher rats in amounts of 0.05 mmol kg-1, 0.10 mmol kg-1 and 0 15 mmol kg-1. The animals were imaged in the head coil of a conventional MRI unit with a pulse sequence designed to emphasize differences in T1 (T1 weighted sequence). The resulting images were analyzed numerically by region-of-interest (ROI) measurements on various organs. The intensity of the kidney image, as indicated by the ROI measurements, increases from ca. 300 arbitrary units for control animals with no contrast agent administered, to ca. 400 (0.05 mmol kg-1) ca 500 (0.10 mmol kg.sup.-1) and ca 600 (0.15 mmol kg-1) as the dose is increased.
The resulting images on the liver showed similar, though less dramatic, effects. A higher dosage of the second-sphere complex (0.15 mmol kg-1) is needed for a statistically significant increase in the ROI level. These results show that the second-sphere agent is capable of increasing image intensity of specific organs relative to background levels.
In accordance with the provisions of the patent statutes, the present invention has been described in what is considered to represent its preferred embodiment. However, it should be noted that the invention can be practiced otherwise than as specifically illustrated and described without departing from its spirit or scope.

Claims (12)

What is claimed is:
1. A second sphere contrast enhancing agent for magnetic resonance imaging of tissue, comprising a highly charged hydrophilic complex having a charge of three minus or greater which consists of a paramagnetic metal ion and at least one 1,2-dihydroxybenzene catecholate ligand coordinated to said paramagnetic metal ion.
2. The second sphere contrast enhancing agent according to claim 1, wherein the paramagnetic metal ion is selected from the group consisting of iron(III) and gadolinium(III).
3. The second sphere contrast enhancing agent according to claim 1, wherein the ligand is prepared from the salt disodium-1,2-dihydroxybenzene-3,5-disulfonate.
4. The second sphere contrast enhancing agent according to claim 1, wherein the paramagnetic metal ion is iron(III) and the ligand is prepared from the salt disodium-1,2-dihydroxybenzene-3,5-disulfonate.
5. The second sphere contrast enhancing agent according to claim 1, wherein the paramagnetic metal ion is gadolinium(III) and the ligand is prepared from the salt disodium-1,2-dihydroxybenzene-3,5-disulfonate.
6. A method for performing magnetic resonance imaging of a patient, comprising:
a) providing a second sphere contrast enhancing agent, comprising a highly charged hydrophilic complex having a charge of three minus or greater which consists of a paramagnetic metal ion and at least one 1,2-dihydroxybenzene catecholate ligands coordinated thereto,
b) administering the second sphere contrast enhancing agent to the patient;
c) forming one or more hydrogen bonds between the paramagnetic metal ion-to-ligand linkage and tissue water molecules of the patient; and
d) subjecting the patient to nuclear magnetic resonance imaging.
7. The method for performing magnetic resonance imaging of a patient according to claim 6, wherein the paramagnetic metal ion is selected from the group consisting of iron(III) and gadolinium(III).
8. The method for performing magnetic resonance imaging of a patient according to claim 6, wherein the ligand is prepared from the salt of disodium-1,2-dihydroxybenzene-3,5-disulfonate.
9. The method for performing magnetic resonance imaging of a patient according to claim 7, wherein the paramagnetic metal ion is iron(III) and the ligand is prepared from the salt disodium-1,2-dihydroxybenzene-3,5-disulfonate.
10. The method for performing magnetic resonance imaging of a patient according to claim 6, wherein the paramagnetic metal ion is gadolinium(III) and the ligand is prepared from the salt disodium-1,2-dihydroxybenzene-3,5-disulfonate.
11. A second sphere contrast enhancing agent for magnetic resortames imaging of tissue, comprising:
a) a paramagnetic metal ion selected (III) and gadolinium (III);
b) at least one 1,2-dihydroxybenzene catecholate ligand coordinated to said paramagnetic metal ion to form a highly charged hydrophilic complex having a charge of three minus or greater, said catecholate ligands prepared from the salt disodium-1,2-dihydroxybenzene-3,5-disulfonate end forming bonding sites for hydrogen bonding where such hydrogen bonding sites include heteroatoms which form paramagnetic metal ion-to-ligand linkages; and
c) water molecules hydrogen bonded to the bonding sites of said catecholate ligands.
12. The second sphere contrast enhancing agent according to claim 11, wherein the bonding sites for hydrogen bonding said water molecules include the heteroatoms which form the paramagnetic metal ion-to-ligand linkages.
US08/406,356 1993-09-14 1995-03-17 Second sphere complexes as relaxation agents for image enhancement in magnetic resonance imaging Expired - Fee Related US5494656A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US08/406,356 US5494656A (en) 1993-09-14 1995-03-17 Second sphere complexes as relaxation agents for image enhancement in magnetic resonance imaging

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12122793A 1993-09-14 1993-09-14
US08/406,356 US5494656A (en) 1993-09-14 1995-03-17 Second sphere complexes as relaxation agents for image enhancement in magnetic resonance imaging

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US12122793A Continuation 1993-09-14 1993-09-14

Publications (1)

Publication Number Publication Date
US5494656A true US5494656A (en) 1996-02-27

Family

ID=22395357

Family Applications (1)

Application Number Title Priority Date Filing Date
US08/406,356 Expired - Fee Related US5494656A (en) 1993-09-14 1995-03-17 Second sphere complexes as relaxation agents for image enhancement in magnetic resonance imaging

Country Status (6)

Country Link
US (1) US5494656A (en)
EP (1) EP0721311A4 (en)
AU (1) AU675013B2 (en)
NO (1) NO961524L (en)
NZ (1) NZ275546A (en)
WO (1) WO1995007653A1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6146615A (en) * 1999-01-11 2000-11-14 The University Of Toledo Contrast agents for image enhancement in magnetic resonance imaging
US6294152B1 (en) 1999-01-11 2001-09-25 The University Of Toledo Iron(III) complexes as contrast agents for image enhancement in magnetic resonance imaging
WO2016209977A1 (en) * 2015-06-22 2016-12-29 The Regents Of The University Of California Polymeric micellar nanoparticles
WO2022035969A1 (en) * 2020-08-11 2022-02-17 Inventure, LLC Reduced metastable complex macrocyclic contrast agents

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880008A (en) * 1985-05-08 1989-11-14 The General Hospital Corporation Vivo enhancement of NMR relaxivity
US5010191A (en) * 1985-08-19 1991-04-23 The Regents Of The University Of California Imaging agents for in vivo magnetic resonance and scintigraphic imaging
US5225282A (en) * 1991-12-13 1993-07-06 Molecular Bioquest, Inc. Biodegradable magnetic microcluster comprising non-magnetic metal or metal oxide particles coated with a functionalized polymer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU656355B2 (en) * 1990-11-21 1995-02-02 Mallinckrodt Medical, Inc. Alkoxyamide derivatized chelates for MRI

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880008A (en) * 1985-05-08 1989-11-14 The General Hospital Corporation Vivo enhancement of NMR relaxivity
US5010191A (en) * 1985-08-19 1991-04-23 The Regents Of The University Of California Imaging agents for in vivo magnetic resonance and scintigraphic imaging
US5225282A (en) * 1991-12-13 1993-07-06 Molecular Bioquest, Inc. Biodegradable magnetic microcluster comprising non-magnetic metal or metal oxide particles coated with a functionalized polymer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Bagyinka et al. Chem. Abstracts, 88:116562f, (1978). *
Rajan et al., Chem. Abstracts, 85:56477h, (1976). *
Rudzitis et al., Chem. Abstracts, 76:37921w, (1971). *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6146615A (en) * 1999-01-11 2000-11-14 The University Of Toledo Contrast agents for image enhancement in magnetic resonance imaging
US6294152B1 (en) 1999-01-11 2001-09-25 The University Of Toledo Iron(III) complexes as contrast agents for image enhancement in magnetic resonance imaging
WO2016209977A1 (en) * 2015-06-22 2016-12-29 The Regents Of The University Of California Polymeric micellar nanoparticles
WO2022035969A1 (en) * 2020-08-11 2022-02-17 Inventure, LLC Reduced metastable complex macrocyclic contrast agents
US11419953B2 (en) 2020-08-11 2022-08-23 Inventure, LLC Reduced metastable complex macrocyclic contrast agents
EP4196174A4 (en) * 2020-08-11 2025-01-29 Inventure, LLC Reduced metastable complex macrocyclic contrast agents

Also Published As

Publication number Publication date
NO961524D0 (en) 1996-04-17
AU675013B2 (en) 1997-01-16
WO1995007653A1 (en) 1995-03-23
AU7955494A (en) 1995-04-03
EP0721311A1 (en) 1996-07-17
NZ275546A (en) 1998-01-26
EP0721311A4 (en) 1996-09-25
NO961524L (en) 1996-05-07

Similar Documents

Publication Publication Date Title
DE3650572T3 (en) CONTRASTANT FOR THE ILLUSTRATION OF THE LIVER GALLING SYSTEM BY NMR CONTRASTING AGENT
SCHUHMANN-GIAMPIERI et al. In vivo and in vitro evaluation of Gd-DTPA-polylysine as a macromolecular contrast agent for magnetic resonance imaging
US4859451A (en) Paramagnetic contrast agents for MR imaging
Schwendener et al. A pharmacokinetic and MRI study of unilamellar gadolinium-, manganese-, and iron-DTPA-stearate liposomes as organ-specific contrast agents
JPH0645632B2 (en) Diamide-DTPA-paramagnetic contrast agent for MR imaging
JPH06506468A (en) Melanin image enhancer
Wan et al. Research progress on manganese complexes as contrast agents for magnetic resonance imaging
Duffield et al. Computer simulation of metal ion equilibria in biofluids. IV. Plutonium speciation in human blood plasma and chelation therapy using polyaminopolycarboxylic acids
EP1126785B1 (en) Manganese compositions and methods for mri
CA2053478C (en) Magnetic resonance imaging agent
US7005517B2 (en) Paramagnetic metal-phthalocyanine complex compounds and contrast agent using the same
US6015545A (en) Manganese containing magnetic resonance contrast agent
US5494656A (en) Second sphere complexes as relaxation agents for image enhancement in magnetic resonance imaging
US6146615A (en) Contrast agents for image enhancement in magnetic resonance imaging
CA2304461C (en) Lipophilic metal complexes for necrosis and infarction imaging
Yon et al. Simple hybrid polymeric nanostructures encapsulating macro-cyclic Gd/Eu based complexes: luminescence properties and application as MRI contrast agent
Kreft et al. Orally administered manganese chloride: enhanced detection of hepatic tumors in rats.
La Cava et al. Synthesis, characterization, and biodistribution of a dinuclear gadolinium complex with improved properties as a blood pool MRI agent
Tweedle et al. Magnetic resonance imaging (MRI) contrast agents
US6294152B1 (en) Iron(III) complexes as contrast agents for image enhancement in magnetic resonance imaging
US11771780B2 (en) Method for preparing an Fe-tCDTA contrast agent and product obtainable by the method
US6495118B1 (en) Lipophilic metal complexes for necrosis and infarction imaging
Nakajima et al. Current Clinical Issues: Deposition
KR100650090B1 (en) Calcium Complexes of Phosphorus-containing Ethylenediamine Derivatives
EP0500732B1 (en) Diagnostic composition comprising a binuclear complex, a method for preparing same, and its use in magnetic resonance imaging

Legal Events

Date Code Title Description
FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

FPAY Fee payment

Year of fee payment: 4

FEPP Fee payment procedure

Free format text: PAYER NUMBER DE-ASSIGNED (ORIGINAL EVENT CODE: RMPN); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
FP Lapsed due to failure to pay maintenance fee

Effective date: 20040227

STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362